Table 3.
Presence and absence of edema by baseline estimated glomerular filtration rate quartiles (n = 393)*
| Estimated Glomerular Filtration Rate† quartile (mL/min/1.73 m2) |
Edema‡ | Placebo (n = 132) |
Ambrisentan | |||
|---|---|---|---|---|---|---|
| 2.5 mg (n = 64) |
5 mg (n = 130) |
10 mg (n = 67) |
Overall (n = 261) |
|||
| 22.19 to ≤60.25 | ||||||
| Yes | 5 (3.8%) | 3 (4.7%) | 9 (6.9%) | 7 (10.4%) | 19 (7.3%) | |
| No | 23 (17.4%) | 16 (25.0%) | 26 (20.0%) | 6 (9.0%) | 48 (18.4%) | |
| 60.26 to ≤71.61 | ||||||
| Yes | 8 (6.1%) | 0 (0%) | 7 (5.4%) | 6 (9.0%) | 13 (5.0%) | |
| No | 28 (21.2%) | 15 (23.4%) | 22 (16.9%) | 9 (13.4%) | 46 (17.6%) | |
| 71.62 to ≤87.40 | ||||||
| Yes | 2 (1.5%) | 3 (4.7%) | 6 (4.6%) | 2 (3.0%) | 11 (4.2%) | |
| No | 28 (21.2%) | 16 (25.0%) | 24 (18.5%) | 14 (20.9%) | 54 (20.7%) | |
| 87.41 to ≤270.13 | ||||||
| Yes | 2 (1.5%) | 1 (1.6%) | 7 (5.4%) | 7 (10.4%) | 15 (19.5%) | |
| No | 26 (19.7%) | 9 (14.1%) | 27 (20.8%) | 15 (22.4%) | 51 (19.5%) | |
*
Baseline estimated glomerular filtration rate missing for 14.
†
Estimated glomerular filtration rate (mL/min/1.73 m2) = 32,788 × serum creatinine−1.154 (µmol/L) × age−0.203 × [1.212 if black] × [0.742 if a woman].
‡
Edema included the following adverse events terms: peripheral edema, edema, pitting edema, gravitational edema, localized edema, anasarca, fluid retention, and fluid overload.